Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | $15.6M | $37.6M | $36.2M | $10.4M | ($173.6M) | $2,224.0K | $192.9M | $214.2M | $211.7M | $393.4M | $307.9M | $333.0M | $600.4M | $387.9M | $594.0M | ($290.3M) | $696.4M | $477.4M | $663.7M | $747.6M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, United Therapeutics Corporation's last 12-month Free Cash Flow is $898.1M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, United Therapeutics Corporation's Free Cash Flow growth was 17.5%. The average annual Free Cash Flow growth rates for United Therapeutics Corporation have been 16.1% over the past three years, N/A over the past five years.
Over the last year, United Therapeutics Corporation's Free Cash Flow growth was 17.5%, which is higher than industry growth of (0.1%). It indicates that United Therapeutics Corporation's Free Cash Flow growth is Good.